Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial
A Phase 1/2 clinical trial shows a 91% response rate in treatment-naïve high-risk MDS and CMML, indicating potential for improved outcomes with novel combinations.
Key Points
The combination of venetoclax and oral decitabine resulted in an overall response rate of 91%.
Complete remission was achieved in 45% of patients with high-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.
Clinical trial utilized a phase I/II design to assess the feasibility of oral decitabine with venetoclax in treating these conditions.
Findings indicate that this combination may lead to improved outcomes for patients, alongside hematopoietic stem-cell transplantation.